BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Douglas Pharmaceuticals To Present At Citigroup Small- And Mid-Cap Conference


3/14/2006 10:23:13 AM

HACKENSACK, N.J., March 13 /PRNewswire-FirstCall/ -- DOV Pharmaceutical, Inc. announced today that Ms. Barbara Duncan, Chief Financial Officer, will present at the Citigroup Small- and Mid-Cap Global Conference on Wednesday, March 15, 2006. Her presentation is scheduled to begin at 3:45 p.m. PST at the Four Seasons at Mandalay Bay in Las Vegas. Ms. Duncan will discuss the development and commercialization strategy for DOV's leading product candidates and data from the Company's late stage clinical development programs. A Web cast of the presentation may be accessed through the DOV Pharmaceutical Web site at http://www.dovpharm.com and Ms. Duncan's presentation will be archived and available on the Investor Relations section of DOV's Web site after the conference for 90 days.

About DOV

DOV is a biopharmaceutical company focused on the discovery, acquisition, development and commercialization of novel drug candidates for central nervous system disorders. Our product candidates address some of the largest pharmaceutical markets in the world including insomnia, pain and depression. Our partner Neurocrine has filed two NDAs for the use of DOV's compound indiplon for the treatment of insomnia.

DOV Pharmaceutical, Inc.

CONTACT: Keri P. Mattox, Director, Investor Relations and CorporateCommunications of DOV Pharmaceutical, Inc., +1-201-968-0980



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES